Moxibustion as an adjuvant for benign prostatic hyperplasia with lower urinary tract symptoms: a protocol for a parallel-group, randomised, controlled pilot trial

Hye-Yoon Lee, Jong-Kil Nam, Sang-Don Lee, Dong-Hoon Lee, Ji-Yeon Han, Young-Ju Yun, Ji-Hye Lee, Hye-Lim Park, Seong-Ha Park, Jung-Nam Kwon, Hye-Yoon Lee, Jong-Kil Nam, Sang-Don Lee, Dong-Hoon Lee, Ji-Yeon Han, Young-Ju Yun, Ji-Hye Lee, Hye-Lim Park, Seong-Ha Park, Jung-Nam Kwon

Abstract

Introduction: This study aims to explore the feasibility of using moxibustion as a supplementary intervention and to assess the sample size for verifying the effectiveness and safety of integrative treatment involving moxibustion compared with conventional treatment for patients with benign prostatic hyperplasia accompanying moderate to severe lower urinary tract symptoms.

Methods and analysis: A total of 60 patients diagnosed with benign prostatic hyperplasia by a urologist based on prostate size, prostate-specific antigen and clinical symptoms will participate of their own free will; urologists will monitor the patients and evaluate their symptoms. The patients will be randomised to either a conventional group or an integrative group with a 1:1 allocation according to computer-generated random numbers concealed in opaque, sealed, sequentially numbered envelopes. Watchful waiting or oral medication including α blocker, 5α-reductase inhibitors or antimuscarinic drugs will be offered as conventional treatment. Integrative treatment will include moxibustion therapy in addition to the conventional treatment. The moxibustion therapy will be conducted twice a week for 4 weeks on the bilateral acupoints SP6, LR3 and CV4 by a qualified Korean medical doctor. The primary outcome will be the International Prostate Symptom Score (IPSS) after eight sessions. The secondary outcomes will be the post-void residual urine volume, the maximum urinary flow rate, IPSS, the results of a Short-Form 36-Question Health Survey after 12 weeks, and the patients' global impression of changes at each visit.

Ethics and dissemination: Written informed consent will be obtained from all participants. This study was approved by the institutional review boards of both Pusan National University Yangsan Hospital and Pusan National University Korean Medicine Hospital. The trial results will be disseminated through open-access journals and conferences.

Trial registration number: NCT02051036.

Keywords: integrative medicine; lower urinary tract symptoms; moxibustion.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Figures

Figure 1
Figure 1
Trial flowchart. BPH, benign prostatic hyperplasia; IPSS, International Prostate Symptom Score; KMD, Korean medical doctor; PSA, prostate-specific antigen; TRUS, transrectal ultrasonography.
Figure 2
Figure 2
Timeframe of the integrative treatment group (I.G) and conventional treatment group (C.G).
Figure 3
Figure 3
Apparatus-type moxibustion on acupoint CV4.
Figure 4
Figure 4
Mini-pillar-type moxibustion on bilateral acupoints SP6 and LR3.

References

    1. Statistics Korea. Prevalence of Self-Recognition on Chronic Disease and Doctor's Diagnosis Rate by General Feature of The Aged (Over 65 Years Old) 2011.
    1. Statistics Korea. Outpatient Benefits by Frequency of Disease (Male). 2013.
    1. McVary KT, Roehrborn CG, Avins AL et al. . Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011;185:1793–803. 10.1016/j.juro.2011.01.074
    1. Oelke M, Bachmann A, Descazeaud A et al. . EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2013;64:118–40. 10.1016/j.eururo.2013.03.004
    1. Shim SR, Kim JH, Choi H et al. . General effect of low-dose tamsulosin (0.2 mg) as a first-line treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia: a systematic review and meta-analysis. Curr Med Res Opin 2015;31:353–65. 10.1185/03007995.2014.980887
    1. Cindolo L, Alvarez-Maestro M, Castellucci R et al. . Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis. World J Urol 2015;33:441–2. 10.1007/s00345-014-1300-y.
    1. Guang-Jun D, Feng-Bin G, Xun-Bo J. α-blockers in the management of acute urinary retention secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. Ir J Med Sci 2015;184:23–30. 10.1007/s11845-014-1094-3
    1. Chapple CR, Montorsi F, Tammela TL et al. . Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol 2011;59:342–52. 10.1016/j.eururo.2010.10.046
    1. Wu YJ, Dong Q, Liu LR et al. . A meta-analysis of efficacy and safety of the new α1A-adrenoceptor-selective antagonist silodosin for treating lower urinary tract symptoms associated with BPH. Prostate Cancer Prostatic Dis 2013;16:79–84. 10.1038/pcan.2012.36
    1. van Kerrebroec P, Jardin A, van Cangh P et al. . Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. Eur Urol 2002;41:54–60; discussion 60-1. 10.1016/S0302-2838(01)00016-1
    1. Djavan B, Chapple C, Milani S et al. . State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004;64:1081–8. 10.1016/j.urology.2004.07.031
    1. Lowe F, Narayan P, Djavan B. Prospective, randomised, multicentre trial to evaluate the rapidity of onset and side effect profile of tamsulosin (TAM) vs terazosin (TER) in men with Benign Prostatic Hyperplasia (BPH). Eur Urol Suppl 2002;1:108 10.1016/S1569-9056(02)80415-8
    1. McConnell JD, Roehrborn CG, Bautista OM et al. . The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387–98. 10.1056/NEJMoa030656
    1. Abrams P, Kaplan S, De Koning Gans HJ et al. . Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006;175(3 Pt 1):999–1004; discussion 04. 10.1016/S0022-5347(05)00483-0
    1. Fu YQ. Clinical observation on deep-oblique acupuncture with long needle at Guanyuan (CV 4) for urinary retention. Zhongguo zhen jiu 2013;33:1071–5.
    1. Wang Y, Liu B, Yu J et al. . Electroacupuncture for moderate and severe benign prostatic hyperplasia: a randomized controlled trial. PLoS ONE 2013;8:e59449 10.1371/journal.pone.0059449
    1. Yu JS, Shen KH, Chen WC et al. . Effects of electroacupuncture on benign prostate hyperplasia patients with lower urinary tract symptoms: a single-blinded, randomized controlled trial. Evid Based Complement Alternat Med 2011;2011:303198 10.1155/2011/303198
    1. Xu ZJ. Efficacy observation on benign prostatic hyperplasia treated with acupuncture and moxibustion. Zhongguo zhen jiu 2014;34:241–4.
    1. Li S, Lu A, Wang Y. Symptomatic comparison in efficacy on patients with benign prostatic hyperplasia treated with two therapeutic approaches. Complement Ther Med 2010;18:21–7. 10.1016/j.ctim.2009.10.002
    1. Kim KM. A literature study of acupuncture and moxibustion therapy in the [the Urine] section (in the Naegyeong Chapter) of [Dong-Ui-Bo-Gam]. J Daejeon Oriental Med 2010;19:129–42.
    1. Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat 2005;4:287–91. 10.1002/pst.185
    1. Hwang MS, Heo KH, Cho HW et al. . Electroacupuncture as a complement to usual care for patients with non-acute pain after back surgery: a study protocol for a pilot randomised controlled trial. BMJ Open 2015;5:e007031 10.1136/bmjopen-2014-007031
    1. Kim KH, Ryu JH, Park MR et al. . Acupuncture as analgesia for non-emergent acute non-specific neck pain, ankle sprain and primary headache in an emergency department setting: a protocol for a parallel group, randomised, controlled pilot trial. BMJ Open 2014;4:e004994 10.1136/bmjopen-2014-004994
    1. Witt CM, Reinhold T, Jena S et al. . Cost-effectiveness of acupuncture treatment in patients with headache. Cephalalgia 2008;28:334–45. 10.1111/j.1468-2982.2007.01504.x
    1. Li D. Perplexities to acupuncture and moxibustion. Shanghai University of TCM Press, 2007:112.
    1. Song FJ, Jiang SH, Zheng SL et al. . [Electroacupuncture for post-stroke urinary incontinence: a multi-center randomized controlled study]. Zhongguo zhen jiu 2013;33:769–73.
    1. Huh J. Donguibogam. South Korea: Donguibogam Publisher, 2005:357.
    1. Korean Acupuncture & Moxibustion Society Textbook Compilation Committee. The acupuncture and moxibustion medicine. Paju, Gyeongi, South Korea: Jipmoon, 2008:253.
    1. Kim JW, Kim TG, Lee JH et al. . A study on the selecting indications of Five—Viscera Source Point Acupuncture in Suwen. J Korean Med Classics 2013;26:23–42. 10.14369/skmc.2013.26.4.023
    1. Yang T, Liu Z, Zhang X. Evaluation on therapeutic effects of electro acupuncture for benign prostatic hyperplasia: A prospective randomized controlled study. Chin J Rehabil Med 2008;23:1028–31.
    1. Liu QG, Wang CY, Jiao S et al. . Electroacupuncture at Zhongji (CV 3) for treatment of benign hyperplasia of prostate: a multi-central randomized controlled study. Zhongguo zhen jiu 2008;28:555–9.
    1. Korean Acupuncture & Moxibustion Society Textbook Compilation Committee. The Acupuncture and Moxibustion Medicine. Paju, Gyeongi, South Korea: Jipmoon, 2008.
    1. Barry MJ, Fowler FJ Jr, O'Leary MP et al. . The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992;148:1549–57; discussion 64.
    1. Choi HR, Chung WS, Shim BS et al. . Translation validity and reliability of I-PSS Korean version. Korean J Urol 1996;37: 659–65.
    1. Hurst H, Bolton J. Assessing the clinical significance of change scores recorded on subjective outcome measures. J Manipulative Physiol Ther 2004;27:26–35. 10.1016/j.jmpt.2003.11.003
    1. Han CW, Lee EJ, Iwaya T et al. . Development of the Korean version of Short-Form 36-Item Health Survey: health related QOL of healthy elderly people and elderly patients in Korea. Tohoku J Exp Med 2004;203:189–94. 10.1620/tjem.203.189
    1. Schafer W, Abrams P, Liao L et al. . Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn 2002;21:261–74. 10.1002/nau.10066
    1. Chung BH. Medical management for benign prostatic hyperplasia. Korean J Urol 2007;48:233–43. 10.4111/kju.2007.48.3.233
    1. Joung JY, Park JK, Park CH et al. . The role of alpha 1 (A) adrenoceptor antagonist tamsulosin for the treatment of patients with benign prostatic hyperplasia: the effect on lower urinary tract symptoms and nocturia. Korean J Urol 2006;47:1–6. 10.4111/kju.2006.47.1.1
    1. Jeong DH, Park YI. Clinical experience of symptomatic management of BPH with terazosin, doxazosin or combination of terazosin and finasteride. Korean J Urol 1998;39:772–6.
    1. Lee ES. A study on utilization of oriental medical care. Korea Institute of Oriental Medicine, 1999:1–5.
    1. Lee SY, Byon YC. The present condition and the improvement method for western medicine-Korean medicine cooperative practice system Korea Institute for Health and Social Affairs, Policy report 1997.
    1. Lamb SE, Williamson EM, Heine PJ et al. . Exercises to improve function of the rheumatoid hand (SARAH): a randomised controlled trial. Lancet 2015;385:421–9. 10.1016/S0140-6736(14)60998-3
    1. Treweek S, Zwarenstein M. Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials 2009;10:37 10.1186/1745-6215-10-37
    1. Godwin M, Ruhland L, Casson I et al. . Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity. BMC Med Res Methodol 2003;3:28 10.1186/1471-2288-3-28

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel